CL King initiated coverage on Axonics Modulation with a new price target
$AXNX
Medical/Dental Instruments
Health Care
CL King initiated coverage of Axonics Modulation with a rating of Buy and set a new price target of $75.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/9/2024 | Outperform → Peer Perform | Wolfe Research | |
| 7/19/2023 | $69.00 | Outperform | Robert W. Baird |
| 7/13/2023 | $70.00 | Overweight | KeyBanc Capital Markets |
| 5/23/2023 | $75.00 | Buy | CL King |
| 4/14/2023 | $75.00 | Buy | Mizuho |
| 3/24/2023 | $71.00 | Hold → Buy | Needham |
| 10/21/2022 | $85.00 | Outperform | RBC Capital Mkts |
| 10/12/2022 | $75.00 | Hold | Jefferies |
15-12G - Axonics, Inc. (0001603756) (Filer)
EFFECT - Axonics, Inc. (0001603756) (Filer)
25-NSE - Axonics, Inc. (0001603756) (Subject)
4 - Axonics, Inc. (0001603756) (Issuer)
4 - Axonics, Inc. (0001603756) (Issuer)
4 - Axonics, Inc. (0001603756) (Issuer)
Kestra Medical Technologies, Inc., a privately held wearable medical device and digital healthcare company, today announced that Raymond W. Cohen has joined the board of directors as a new independent board director. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240725221367/en/Kestra Medical Technologies, Inc. announced that Raymond W. Cohen has joined the board of directors as a new independent board director. (Photo: Business Wire) Brian Webster, President & CEO of Kestra said, "Ray is one of the most experienced and accomplished leaders in the medical device industry with multiple decades of success in developing and commer
BiVACOR, Inc., a clinical-stage medical technology company developing a total artificial heart (TAH), today announced that Raymond W. Cohen has been appointed chairman of its board of directors. Mr. Cohen is an accredited public company director with over 40 years of experience in the life sciences industry. He currently serves as chief executive officer and member of the board of directors of Axonics, Inc. (NASDAQ:AXNX), an Irvine, Calif. based global medical technology company that he co-founded in 2013 and took public in October 2018. Axonics ranked No. 1 on the 2021 Deloitte Technology Fast 500™ and the 2022 Financial Times ranking of the 500 fastest growing companies in the Americas.
Axonics, Inc. (NASDAQ:AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that Dan L. Dearen, president and chief financial officer, is retiring from the company. Kari Keese, vice president of finance and accounting, will succeed Mr. Dearen on Monday, October 2. "On behalf of the Axonics team and the board of directors, I want to thank Dan, my co-founder and longtime colleague, for his many contributions to the company over the last 10 years," said Raymond W. Cohen, chief executive officer. "Dan has played an instrumental role in Axonics' success and the significant value that